Details of the Drug-Related molecule(s) Expression Atlas

General Information of Drug (ID: DMQG7ZM)

Drug Name
Belagenpumatucel-L Drug Info
Synonyms Lucanix (TN)
Indication
Disease Entry ICD 11 Status REF
Non-small-cell lung cancer 2C25.Y Phase 3 [1]
Small-cell lung cancer 2C25.Y Phase 3 [1]
Cross-matching ID
TTD Drug ID
DMQG7ZM

Molecule(s) Related to This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
TGF beta-2 messenger RNA (TGFB2 mRNA) TTI0KH6 TGFB2_HUMAN Not Available [2]

The Expression Level of Molecule(s) in Normal Tissue of Major ADME-Related Organs

Molecule Molecule Type Gene Name Liver Colon Kidney Small Intestine
TGF beta-2 messenger RNA (TGFB2 mRNA) DTT TGFB2 5.307 4.868 4.76 5.406
Molecule Expression Atlas in Normal Tissue of Major ADME-related organs

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

The Studied Disease Non-small-cell lung cancer
ICD Disease Classification 2C25.Y
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
TGF beta-2 messenger RNA (TGFB2 mRNA) DTT TGFB2 1.51E-17 -0.53 -0.77
Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1 ClinicalTrials.gov (NCT00676507) Phase III Lucanix Vaccine Therapy in Advanced Non-small Cell Lung Cancer (NSCLC) Following Front-line Chemotherapy. U.S. National Institutes of Health.
2 National Cancer Institute Drug Dictionary (drug id 590662).